Clinical trial
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity
Recruiting now · Phase 4 · 1 countries · Registry ID NCT07728383
Recruiting nowPhase 4Interventional
What this study is about
This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to 65 Years
SexAll
Healthy volunteersNot accepted
ConditionObesity & Overweight
Full registry criteria
Inclusion Criteria: * Body Mass Index 30 to 45 Exclusion Criteria: * Type 2 Diabetes Mellitus * Multiple Endocrine Neoplasia Type 2 * Medullary thyroid cancer
Treatments and study arms
Semaglutide 6 mg liquid emulsion formulation
Drug
Semaglutide 6 mg liquid emulsion formulation daily
Wegovy® (semaglutide) Tablet
Drug
Wegovy® (semaglutide) Tablet 25 mg daily
Placebo liquid emulsion formulation
Drug
Placebo liquid emulsion formulation daily
Primary outcomes
Percent body weight change from baseline24 weeks
Percentage change in body weight at 24 weeks from baseline by calibrated scale.
Study locations
1 locations were listed when this page was built. The first 40 are shown.
Clinical Research Institute of Minnesota🇺🇸 Minneapolis, Minnesota, United States
Gary D Berman, M.D.Contact
Kristin Weber, FNP-CContact
Gary D Berman, M.D.Principal Investigator